miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment

Pigment Cell and Melanoma Research

Volumn 28, Issue 4, 2015, Pages 431-441

  Liu, Shujing ^a   Tetzlaff, Michael T ^b   Wang, Tao ^c   Yang, Ruifeng ^a   Xie, Lin ^a,d   Zhang, Gao ^c   Krepler, Clemens ^c   Xiao, Min ^c   Beqiri, Marilda ^c   Xu, Wei ^e   Karakousis, Giorgos ^f   Schuchter, Lynn ^f   Amaravadi, Ravi K ^e,f   Xu, Weiting ^g   Wei, Zhi ^g   Herlyn, Meenhard ^c   Yao, Yuan ^a   Zhang, Litao ^a,h   Wang, Yingjie ⁱ   Zhang, Lin ^e   Xu, Xiaowei ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WISTAR INSTITUTE   (United States)

^d THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g University Heights   (United States)

^h TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

ⁱ ZHEJIANG UNIVERSITY   (China)

Author keywords

Bmi1; BRAF inhibitor; Epithelial mesenchymal transition; Melanoma; MiR 200c

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER G5; BETA TUBULIN; BMI1 PROTEIN; MESSENGER RNA; MICRORNA 200C; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB2; TUBULIN BETA 3; UNCLASSIFIED DRUG; UVOMORULIN; VEMURAFENIB; B RAF KINASE; BMI1 PROTEIN, HUMAN; INDOLE DERIVATIVE; MICRORNA; MIRN200 MICRORNA, HUMAN; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOLES; MICE; MICRORNAS; PHENOTYPE; POLYCOMB REPRESSIVE COMPLEX 1; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930923522     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12379     Document Type: Article

References (48)

1. Chen, Z.S., and Tiwari, A.K. (2011). Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 278, 3226-3245.
2. Cui, H., Hu, B., Li, T., Ma, J., Alam, G., Gunning, W.T., and Ding, H.F. (2007). Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am. J. Pathol. 170, 1370-1378.
3. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E. Jr, You, M.J., Depinho, R.A., Mcmahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
4. Davies, T.J., Wadhawan, J.D., and Compton, R.G. (2002). Photoelectrochemical dechlorination of phenols. Photochem. Photobiol. Sci. 1, 902-906.
5. Du, P., Kibbe, W.A., and Lin, S.M. (2008). lumi: a pipeline for processing Illumina microarray. Bioinformatics 24, 1547-1548.
6. Dykxhoorn, D.M., Wu, Y., Xie, H., Yu, F., Lal, A., Petrocca, F., Martinvalet, D., Song, E., Lim, B., and Lieberman, J. (2009). miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS ONE 4, e7181.
7. Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
8. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
9. Franco, A.T., Malaguarnera, R., Refetoff, S. et al. (2011). Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc. Natl Acad. Sci. USA 108, 1615-1620.
10. Glinsky, G.V., Berezovska, O., and Glinskii, A.B. (2005). Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115, 1503-1521.
11. Gottesman, M.M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.
12. Gottesman, M.M., Fojo, T., and Bates, S.E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58.
13. Gregory, P.A., Bert, A.G., Paterson, E.L., Barry, S.C., Tsykin, A., Farshid, G., Vadas, M.A., Khew-Goodall, Y., and Goodall, G.J. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601.
14. Guo, B.H., Feng, Y., Zhang, R., Xu, L.H., Li, M.Z., Kung, H.F., Song, L.B., and Zeng, M.S. (2011). Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol. Cancer. 10, 10.
15. Hayry, V., Tynninen, O., Haapasalo, H.K. et al. (2008). Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol. Appl. Neurobiol. 34, 555-563.
16. Hsu, T., Trojanowska, M., and Watson, D.K. (2004). Ets proteins in biological control and cancer. J. Cell. Biochem. 91, 896-903.
17. Huber, G.F., Albinger-Hegyi, A., Soltermann, A., Roessle, M., Graf, N., Haerle, S.K., Holzmann, D., Moch, H., and Hegyi, I. (2011). Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma. Cancer 117, 4659-4670.
18. Jacobs, J.J., and Van Lohuizen, M. (2002). Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim. Biophys. Acta 1602, 151-161.
19. Jiang, C.C., Lai, F., Thorne, R.F., Yang, F., Liu, H., Hersey, P., and Zhang, X.D. (2011). MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin. Cancer Res. 17, 721-730.
20. Kopp, F., Oak, P.S., Wagner, E., and Roidl, A. (2012). miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS ONE 7, e50469.
21. La Porta, C.A. (2009). Mechanism of drug sensitivity and resistance in melanoma. Curr. Cancer Drug Targets 9, 391-397.
22. Liu, S., Kumar, S.M., Martin, J.S., Yang, R., and Xu, X. (2011). Snail1 mediates hypoxia-induced melanoma progression. Am. J. Pathol. 179, 3020-3031.
23. Liu, S., Tetzlaff, M.T., Cui, R., and Xu, X. (2012). miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am. J. Pathol. 181, 1823-1835.
24. Liu, S.J., Sun, Y.M., Tian, D.F., He, Y.C., Zeng, L., He, Y., Ling, C.Q., and Sun, S.H. (2008). Downregulated NM23-H1 expression is associated with intracranial invasion of nasopharyngeal carcinoma. Br. J. Cancer 98, 363-369.
25. Luo, C., Weber, C.E., Osen, W., Bosserhoff, A.K., and Eichmuller, S.B. (2014). The role of microRNAs in melanoma. Eur. J. Cell Biol. 93, 11-22.
26. Ma, J., Dong, C., and Ji, C. (2010). MicroRNA and drug resistance. Cancer Gene Ther. 17, 523-531.
27. Mihic-Probst, D., Kuster, A., Kilgus, S. et al. (2007). Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int. J. Cancer 121, 1764-1770.
28. Nazarian, R., Shi, H., Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
29. Onder, T.T., Kara, N., Cherry, A. et al. (2012). Chromatin-modifying enzymes as modulators of reprogramming. Nature 483, 598-602.
30. Paraiso, K.H., Xiang, Y., Rebecca, V.W. et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760.
31. Paranjape, A.N., Balaji, S.A., Mandal, T., Krushik, E.V., Nagaraj, P., Mukherjee, G., and Rangarajan, A. (2014). Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. BMC Cancer 14, 785.
32. Park, I.K., Qian, D., Kiel, M., Becker, M.W., Pihalja, M., Weissman, I.L., Morrison, S.J., and Clarke, M.F. (2003). Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302-305.
33. Park, S.M., Gaur, A.B., Lengyel, E., and Peter, M.E. (2008). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894-907.
34. Piunti, A., Rossi, A., Cerutti, A. et al. (2014). Polycomb proteins control proliferation and transformation independently of cell cycle checkpoints by regulating DNA replication. Nat. Commun. 5, 3649.
35. Poulikakos, P.I., Persaud, Y., Janakiraman, M. et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390.
36. Saxena, M., Stephens, M.A., Pathak, H., and Rangarajan, A. (2011). Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2, e179.
37. Segal, R.A. (2003). Selectivity in neurotrophin signaling: theme and variations. Annu. Rev. Neurosci. 26, 299-330.
38. She, Q.B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K.M., Leander, K.R., Defeo-Jones, D., Huber, H.E., and Rosen, N. (2008). Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3, e3065.
39. Shimono, Y., Zabala, M., Cho, R.W. et al. (2009). Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603.
40. Song, L.B., Li, J., Liao, W.T. et al. (2009). The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest. 119, 3626-3636.
41. Sullivan, R.J., and Flaherty, K.T. (2013). Resistance to BRAF-targeted therapy in melanoma. Eur. J. Cancer 49, 1297-1304.
42. Thiery, J.P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454.
43. Thiery, J.P., and Sleeman, J.P. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131-142.
44. Tucci, M.G., Lucarini, G., Brancorsini, D., Zizzi, A., Pugnaloni, A., Giacchetti, A., Ricotti, G., and Biagini, G. (2007). Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. Br. J. Dermatol. 157, 1212-1216.
45. Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
46. Wang, Z., Li, Y., Ahmad, A., Azmi, A.S., Kong, D., Banerjee, S., and Sarkar, F.H. (2010). Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist. Updat. 13, 109-118.
47. Wellner, U., Schubert, J., Burk, U.C. et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487-1495.
48. Wu, X., Liu, X., Sengupta, J., Bu, Y., Yi, F., Wang, C., Shi, Y., Zhu, Y., Jiao, Q., and Song, F. (2011). Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells. Indian J. Exp. Biol. 49, 105-112.